Table 5. Comparison of our study with previous studies.

NR: not reported. LRR: locoregional recurrence.DM: distant metastasis. PD: progressive disease. AWD: alive with disease. DOD: died of disease. NED: no evidence of disease.

Sl No	Study	No of cases	Median age (years)	cT stage -%	Clinical nodal positivity (%)	pT stage- %	Pathological nodal positivity (%)	Triple-negative receptor status (%)	Follow-up (months)	Outcome	Patient status
1.	Esbah et al. [9]	14	45.5	cT1/T2- 42.8	NR	pT1- 0	64.3	71.4	52	LRR- 7.1%	PD- 50%
				cT3/T4- 57.2		pT2- 30.8				DM- 57.1%	Death- 35.7%
						pT3- 61.5
						pT4- 7.7
2.	Hasbay et al. [16]	38	55.34	NR	NR	pT1- 7.9	49	78.9	34	LRR- NR	Alive- 81.5%
						pT2- 52.6				DM- 28.9%	Dead- 18.5%
						pT3- 10.5
						pT4- 7.9
3.	Samoon et al. [17]	42	54	cT1/T2- 73.8	45.2	NR	53.1	38.1	34	LRR- 5.2%	AWD- 7.7%
				cT3/T4- 26.2						DM- 24.32%	DOD- 17.9%
											NED- 69.2%
4.	Erjan et al. [15]	81	48	NR	NR	pT1/T2- 64.2	34.6	67.9	54	LRR- 18.5%	AWD- 4.9%
						pT3/T4- 35.8				DM- 34.6%	DOD- 30.9%
											NED- 55.6%
5.	Current study	28	47	cT1/T2- 39.3	39.3	pT0/T1- 0	32	53.7	13	LRR- 3.6%	AWD- 3.6%
				cT3/T4- 60.7		pT2- 48				DM- 32.1%	DOD- 32.1%
						pT3- 24					NED- 57.1%
						pT4- 28